ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference Press release LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 13, 2017
ProQR to Present at EuroTIDES Conference Press release LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 31, 2017
ProQR Announces Pricing of Initial Public Offering Press release LEIDEN, Netherlands, Sept. 18, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share. September 18, 2014
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. October 15, 2019
ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference Press release LEIDEN, The Netherlands, June 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 04, 2018
ProQR Announces Proposed Public Offering of Ordinary Shares Press release LEIDEN, the Netherlands, Nov. November 13, 2017
ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer Press release Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally October 05, 2020
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO Press release LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. October 07, 2019
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. September 05, 2018
ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- May 09, 2023
